Details

Primerjava naložbenega zavarovanja Junior s konkurenčnimi zavarovanji v Sloveniji : diplomsko delo
ID Štefančič, Miha (Author), ID Hartman, Rasto (Mentor) More about this mentor... This link opens in a new window

URLURL - Presentation file, Visit http://www.cek.ef.uni-lj.si/u_diplome/stefancic4623.pdf This link opens in a new window

Language:Slovenian
Keywords:Slovenija, zavarovalstvo, življenjsko zavarovanje, investicije, investicijski skladi, konkurenca, komparacije
Work type:Undergraduate thesis
Typology:2.11 - Undergraduate Thesis
Organization:EF - School of Economics and Business
Place of publishing:Ljubljana
Publisher:[M. Štefančič]
Year:2011
Number of pages:III, 42 str.
PID:20.500.12556/RUL-16183 This link opens in a new window
UDC:368
COBISS.SI-ID:20662502 This link opens in a new window
Publication date in RUL:11.07.2014
Views:1927
Downloads:208
Metadata:XML DC-XML DC-RDF
:
ŠTEFANČIČ, Miha, 2011, Primerjava naložbenega zavarovanja Junior s konkurenčnimi zavarovanji v Sloveniji : diplomsko delo [online]. Bachelor’s thesis. Ljubljana : M. Štefančič. [Accessed 17 April 2025]. Retrieved from: http://www.cek.ef.uni-lj.si/u_diplome/stefancic4623.pdf
Copy citation
Share:Bookmark and Share

Secondary language

Language:Unknown
Keywords:Slovenia, insurance, life insurance, investments, investment funds, competition, comparisons

Similar documents

Similar works from RUL:
  1. ǂThe ǂrole of loyalty cards for consumers
  2. The impact of inflation on consumer behavior of millennials
  3. ǂThe ǂrole of the Instagram social medium in consumer buying behavior
  4. Odnos porabnikov do subliminalnega oglaševanja in vpliv subliminalnih sporočil na nakupno odločitev
  5. Sustainable orientation of consumers when purchasing apparel
Similar works from other Slovenian collections:
  1. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small cell lung cancer
  2. Outsourcing predictive biomarker testing in non-small cell carcinoma
  3. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  4. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  5. NSCLC molecular testing in Central and Eastern European countries

Back